Join Kevin DeJong, Huiya Wu, and David Chen in our next webinar, “An Overview of the Biosimilars Market in China, and Comparison with the US Market” on December 17th at 12:30 PM EST.
Since China’s NMPA approved the first biosimilar in 2019, more than 60 biosimilars have been approved in China. In the United States, the first biosimilar was approved by FDA in 2015, and there are now more than 80 biosimilar products approved by FDA. Join us as we provide an overview of the players, products, and regulatory and legal schemes of the biosimilars market in China and how it compares to the U.S. market.
Register today for this CLE accredited webinar using this link.
Stay tuned for more upcoming sessions exploring other timely and thought-provoking topics in the months ahead!